GlassScriptPhysician profile
Aubrey Allen
NPI 1598128902
$9,288.36
in general payments reported to CMS, 2019-2025
38 companies · $1,189 in 2025
The $1,189 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2021: $495 · 2022: $4,304 · 2023: $1,418 · 2024: $1,722 · 2025: $1,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,228 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,228.32 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,000.00 | 2022 | |
| Janssen Biotech, INC. | $902.07 | 2021-2025 | Erleada, Akeega |
| Medtronic, INC. | $836.40 | 2021-2025 | Interstim |
| Dendreon Pharmaceuticals LLC | $501.90 | 2022-2025 | Provenge |
| Abbvie INC. | $403.56 | 2022-2025 | Botox |
| Astellas Pharma US INC | $387.16 | 2021-2025 | Xtandi |
| Boston Scientific Corporation | $318.06 | 2019-2024 | Tria Firm |
| Endo Pharmaceuticals INC. | $313.96 | 2021-2024 | Xiaflex, Aveed, Edex |
| Sumitomo Pharma America, INC. | $300.40 | 2023-2025 | Orgovyx, Gemtesa |
| Pfizer INC. | $299.08 | 2019-2025 | |
| Urogen Pharma, INC. | $267.19 | 2021-2025 | Jelmyto |
| Axonics, INC. | $203.09 | 2022-2024 | Axonics |
| Procept Biorobotics Corporation | $185.21 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Bayer Healthcare Pharmaceuticals INC. | $179.19 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $113.36 | 2024-2025 | Prolaris |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $111.63 | 2024-2025 | Xiaflex, Aveed |
| Olympus America INC. | $96.72 | 2024 | Itind System |
| Urovant Sciences INC | $95.19 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $88.49 | 2024-2025 | |
| Baxter Healthcare | $77.57 | 2021-2025 | Perclot |
| Merck Sharp & Dohme LLC | $76.45 | 2021-2025 | Lynparza, Keytruda |
| Myovant Sciences INC. | $71.82 | 2021-2022 | |
| Tolmar, INC. | $59.41 | 2023-2025 | Eligard, Jatenzo |
| Antares Pharma, INC. | $46.90 | 2022 | |
| Allergan, INC. | $40.09 | 2021 | |
| Ethicon US, LLC | $38.78 | 2022 | |
| Teleflex LLC | $35.88 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $35.26 | 2024-2025 | Lynparza |
| Photocure INC | $30.15 | 2023-2024 | Cysview |
| Becton, Dickinson and Company | $29.85 | 2024 | Arista Ah Flexitip |
| Clarus Therapeutics INC. | $29.67 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $23.74 | 2022 | |
| 180 Medical, INC. | $21.83 | 2025 | Gentlecath Glide |
| Hollister Incorporated | $20.01 | 2022 | |
| Calyxo, INC. | $18.81 | 2025 | Cvac Aspiration System |
| Telix Pharmaceuticals | $15.96 | 2024 | Illuccix |
| Ambu INC. | $13.52 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aubrey Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.